U.S. Markets open in 1 hr 8 mins
  • S&P Futures

    3,774.75
    -14.75 (-0.39%)
     
  • Dow Futures

    30,667.00
    -114.00 (-0.37%)
     
  • Nasdaq Futures

    11,467.25
    -62.25 (-0.54%)
     
  • Russell 2000 Futures

    1,700.40
    -7.60 (-0.44%)
     
  • Crude Oil

    108.79
    +3.03 (+2.86%)
     
  • Gold

    1,787.80
    -19.50 (-1.08%)
     
  • Silver

    19.58
    -0.78 (-3.82%)
     
  • EUR/USD

    1.0425
    -0.0058 (-0.5525%)
     
  • 10-Yr Bond

    2.9720
    0.0000 (0.00%)
     
  • Vix

    28.69
    +0.53 (+1.88%)
     
  • GBP/USD

    1.2028
    -0.0147 (-1.2064%)
     
  • USD/JPY

    135.1160
    -0.6120 (-0.4509%)
     
  • BTC-USD

    19,217.58
    +125.28 (+0.66%)
     
  • CMC Crypto 200

    412.77
    -18.70 (-4.33%)
     
  • FTSE 100

    7,151.48
    -17.80 (-0.25%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

PRVB LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Provention Bio, Inc.

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - July 16, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021.


If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/provention-bio-inc-loss-submission-form?prid=17722&wire=5

Allegations against PRVB include that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the teplizumab Biologics License Application ("BLA") was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you suffered a loss in Provention Bio you have until July 20, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/90490